Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL615351 | 0.79 | OPRM1 (0.51) | MEN1CYP2C9KMT2AACHEALDH1A1 | |
| SCHEMBL13130325 | 0.77 | OPRM1 (0.35) | KMT2AACHEALDH1A1OPRM1OPRK1 | |
| SCHEMBL612783 | 0.77 | MEN1 (0.44) | MEN1CYP2C9KMT2AALDH1A1OPRM1 | |
| SCHEMBL614816 | 0.76 | MEN1 (0.35) | MEN1CYP2C9KMT2AALDH1A1OPRM1 | |
| SCHEMBL11796632 | 0.76 | KCNA3 (0.48) | MEN1CYP2C9KMT2AOPRM1OPRK1 | |
| SCHEMBL614812 | 0.75 | MEN1 (0.43) | MEN1CYP2C9KMT2AALDH1A1OPRM1 | |
| SCHEMBL615016 | 0.75 | MEN1 (0.43) | MEN1CYP2C9KMT2AALDH1A1OPRM1 | |
| SCHEMBL613629 | 0.75 | ALDH1A1 (0.56) | MEN1KMT2AALDH1A1OPRM1OPRK1 | |
| SCHEMBL613248 | 0.74 | MEN1 (0.63) | MEN1CYP2C9KMT2AALDH1A1OPRM1 | |
| SCHEMBL613750 | 0.74 | CA12 (0.39) | MEN1CYP2C9KMT2AALDH1A1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267689-A1 | 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N. V. (BE) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267689-A1 | 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | CCR2, CCR1, CCR5 | MEN1 4312/4885CYP2C9 1738/4885KMT2A 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.